Cargando…

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?

Detalles Bibliográficos
Autores principales:	Pitt, Bertram, Bhatt, Deepak L, Metra, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712026/ https://www.ncbi.nlm.nih.gov/pubmed/35979811 http://dx.doi.org/10.1093/eurheartj/ehac417

Ejemplares similares

The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
por: Pitt, Bertram, et al.
Publicado: (2021)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

What Does SGLT2 Inhibition Add in Managing Hyponatremia Secondary to Syndrome of Inappropriate Antidiuresis (SIAD)?
por: Jalal, Fadzliana Hanum, et al.
Publicado: (2021)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021)

The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
por: Genuardi, Michael V., et al.
Publicado: (2021)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?
por: Verma, Subodh
Publicado: (2020)

Understanding the Benefits of SGLT2 Inhibition: Direct Effect on Epicardial Adipose Tissue
por: Vega, Rick B.
Publicado: (2023)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Nephroprotection by SGLT2 Inhibition: Back to the Future?
por: De Nicola, Luca, et al.
Publicado: (2020)

Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review
por: Delgado, Elías, et al.
Publicado: (2022)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
por: Saad, Muhammad, et al.
Publicado: (2018)

SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
por: Cardoso, Rhanderson, et al.
Publicado: (2021)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2
por: Powell, David R, et al.
Publicado: (2015)

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
por: Mantsounga, Chris Sorel, et al.
Publicado: (2019)

Implications of SGLT Inhibition on Redox Signalling in Atrial Fibrillation
por: Bode, David, et al.
Publicado: (2021)

SGLT2 inhibition reduces myocardial oxygen consumption
por: Søndergaard, Esben, et al.
Publicado: (2022)

364 Beneficial Actions of SGLT2 Inhibition and H2S Therapy in Heart Failure with Preserved Ejection Fraction
por: Doiron, Jake, et al.
Publicado: (2023)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Pabel, Steffen, et al.
Publicado: (2021)

Lack of durable natriuresis and objective decongestion following SGLT2 inhibition in randomized controlled trials of patients with heart failure
por: Packer, Milton
Publicado: (2023)

Cognitive Deficit in Heart Failure and the Benefits of Aerobic Physical Activity
por: Rêgo, Maria Luíza de Medeiros, et al.
Publicado: (2018)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015)

SGLT2 inhibition to address the unmet needs in diabetic nephropathy
por: Barutta, Federica, et al.
Publicado: (2019)

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
por: Hædersdal, Sofie, et al.
Publicado: (2020)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
por: Oh, Chang-Myung, et al.
Publicado: (2019)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
por: Palmiero, Giuseppe, et al.
Publicado: (2021)

Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
por: Voorrips, Suzanne N., et al.
Publicado: (2022)

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
por: De Lorenzi, Andrea Beatriz, et al.
Publicado: (2023)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials
por: Williams, David M., et al.
Publicado: (2020)

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
por: Moura, Filipe A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dl0034r4bcavlcq7qschta0sj4